Australia's most trusted
source of pharma news
Friday, 29 May 2026
Posted 28 May 2026 PM
Beijing headquartered InnoCare Pharma has confirmed the TGA’s approval of Hibruka, marking the third new BTK inhibitor to be greenlighted for use in Australia just this month.
It joins Novartis' Rhapsido and Sanofi’s Cenrifki, which were both registered in Australia this month for chronic spontaneous urticaria and multiple sclerosis (MS), respectively.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.